ASP2998 / Astellas, Sutro Biopharma - LARVOL DELTA

Session III: ADC/iADC: (TM) ASP2998, a TROP2-targeted ADC with Dual Payloads-Preclinical Data (SITC 2026) - No abstract available

ADC • Preclinical • Oncology

ASP2998, a trophoblast cell-surface antigen 2 (TROP2)–targeted immunostimulatory antibody-drug conjugate with dual payloads, in patients with locally advanced unresectable or metastatic solid tumors: A phase 1b/2 study. (ASCO 2026) - P1/2 | "ASP2998 is a dual-payload (topoisomerase I inhibitor plus stimulator of interferon genes [STING] agonist) immunostimulatory ADC targeting TROP2...Eligible DEXP pts with urothelial carcinoma include those who have received ≤3 prior lines of therapy and progressed on or after enfortumab vedotin plus pembrolizumab...Recruitment is ongoing with 196 planned pts (36 in DESC; 160 in DEXP). ClinicalTrials.Gov Identifier: NCT07287995."

ADC • Clinical • First-in-human • Metastases • P1/2 data • Breast Cancer • Gastric Cancer • HER2 Negative Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Urothelial Cancer • HER-2 • PD-L1 • STING • TACSTD2

ASP2998, a TROP2-targeted immunostimulatory antibody drug conjugate (iADC) with dual payloads, demonstrates potent efficacy and a favorable safety profile in nonclinical models (AACR 2026) - "ASP2998 is a first-in-class dual payload iADC that combines cytotoxic and immuno-stimulatory mechanisms to enhance antitumor efficacy and promote durable antitumor immunity while demonstrating a favorable safety profile in nonhuman primates. A first-in-human (FiH) clinical study is planned."

ADC • Clinical • First-in-human • Oncology • CD4 • CD69 • CD8 • CD80 • GZMB • IFNG • IL1B • IL6 • TACSTD2 • TNFA

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors (clinicaltrials.gov) - P1/2 | N=428 | Recruiting | Sponsor: Astellas Pharma Global Development, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Breast Cancer • Esophageal Cancer • Gastric Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Urothelial Cancer • HER-2 • PD-1 • PD-L1 • STING

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors (clinicaltrials.gov) - P1/2 | N=428 | Not yet recruiting | Sponsor: Astellas Pharma Global Development, Inc.

Monotherapy • New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Urothelial Cancer